RELATED PARTY TRANSACTIONS

6 Months Ended

Jun. 30, 2022

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS

NOTE 12—RELATED PARTY TRANSACTIONS

MSK is a shareholder of the Company. Under the MSK License Agreement, the SADA License Agreement, the CD33 License Agreement, the MabVax Agreement and various other supporting agreements with MSK, the Company has expensed costs in the total amount of $1,434,000 and $1,157,000 in the three months ended June 30, 2022 and 2021, respectively, for milestones, minimum royalties, and research and development costs. The Company expensed costs in the total amounts of $2,808,000 and $2,105,000 in the six months ended June 30, 2022 and 2021, respectively, under these agreements with MSK. Please refer to NOTE 9—LICENSE AGREEMENTS AND COMMITMENTS for additional details on the Company’s agreements with MSK. As of June 30, 2022, the Company had a total of $345,000 recorded as accounts payable, $5,341,000 as accrued liabilities, thereby totaling $5,686,000 due to MSK. As of December 31, 2021, the Company had a total of $748,000 recorded as accounts payable, $5,443,000 as accrued liabilities, thereby totaling $6,191,000 due to MSK.